Oxford BioDynamics PLC (AIM:OBD) shares jumped over 118% after Pfizer published data confirming the effectiveness of the company’s EpiSwitch blood-based biomarkers in monitoring tumour status and treatment response in bladder cancer patients.
The findings, from the JAVELIN Bladder 100 Trial involving 496 patients, were featured in the journal Cancers.
The trial showed that EpiSwitch biomarkers strongly correlate with the immune profiles of tumours, distinguishing between high and low immune activity, key factors in guiding cancer treatment.
Unlike traditional tissue biopsies, EpiSwitch offers a less invasive way to assess a patient’s immune response, potentially helping doctors identify those most likely to benefit from specific therapies.
Already used in prostate cancer testing, this technology could transform cancer diagnosis and monitoring across multiple types.
Oxford BioDynamics said the results underline its growing role in precision medicine and position it well for expansion in the cancer diagnostics market.
Dr Alexandre Akoulitchev, OBD’s chief scientific officer, described the study as a powerful endorsement of their platform.
The stock rose 0.31p to 0.57p, but was still well down from 8p a year ago.
** Update: share price updated **